Terminology & Classifications News

Filtered by SNOMED CT Remove tag search

  • Delay to the release of the 34.0.0 SNOMED CT UK Edition

    Published: June 2022

    Dear colleague,

    Please note that due to the integration of the new SNOMED CT International release and additional requirements to support the Monkeypox outbreak there has been a delay to the production of the 34.0.0 SNOMED CT UK Edition.

    This will delay the release of the:

    • SNOMED CT International Edition
    • SNOMED CT UK Clinical Extension (including the SNOMED CT to ICD-10 and OPCS-4.9 maps)
    • SNOMED CT UK Drug Extension
    • SNOMED CT UK Pathology Extension

    The 34.0.0 SNOMED CT UK Edition will now be published on Friday 22 July 2022, instead of its planned release date of Wednesday 13 July 2022.

    NHS Digital is sorry for any inconvenience that this will cause you.

    Kind regards

    Terminology and Classifications Delivery Service

    Read all news articles

    By Katy Park 5 months ago

    Read this article

  • Notification of SNOMED CT UK Clinical Edition MICRO release 03-Nov-2021

    NHS Digital intend to release an unscheduled SNOMED CT UK Clinical Edition MICRO release on 03-Nov-2021.

    This release is to support urgent COVID-19 pandemic requirements. The release contains 3 additional concepts.

    • Application for medical exemption from COVID-19 vaccination approved
    • Application for medical exemption from COVID-19 vaccination rejected
    • VITT - vaccine-induced immune thrombotic thrombocytopenia

    The release will be available on TRUD as normal and will have a Release ID of 32.6.0 with an Effective Time of 27-Oct-2021.

    Further information on the content of this release will be made available at the point of release.

    Kind regards, 

    Terminology and Classifications Delivery Service

    Read All News Articles

    By Claire Fennell 1 year ago

    Read this article

  • Changes to 2021/22 SNOMED CT and NICIP releases

    Published June 2021

    Dear Colleague,

    After a review of our Terminology Service we’ve introduced some changes to 2021/22 SNOMED CT UK Clinical Edition and National Interim Clinical Imaging Procedure (NICIP) releases.

    Please find more information here

    Kind regards,

    Terminology and Classifications Delivery Service.

    Read All News Articles

    By Claire Fennell 1 year ago

    Read this article

  • COVID-19 Vaccination Codes

    Published March 2021

    Dear Colleague, 

    1324761000000100

    Document Change Log

    Date

    Version

    Description

     

    13/11/2020

    1.0

    FINAL document approved by NHS Digital COVID-19 vaccine programme

    Jeremy Rogers

    Jo Goulding

    Helen Harger

    26/11/2020

    1.1

    Updated dm+d descriptions for ‘Courageous’ – now ‘COVID-19 mRNA Vaccine BNT162b2’

    Jo Goulding

    07/12/2020

    1.2

    ·       embedded hyperlinks to TermBrowser updated (now agnostic of SNOMED release)

    ·       minor typo and other text corrections

    ·       Addition of new pack size for BNT162b2 vaccine to allow GTIN addition (2D datamatrix will be on the outer box of 195vials, not on individual vials)

    Jeremy Rogers

    Jo Goulding

    13/12/2020

    1.3

    Addition of new dm+d concepts for “Astute” vaccine (Janssen/J&J)

    ·       Additions in dm+d release 14/12/2020

    ·       Due in SNOMED CT Browser February 2021

    Jo Goulding

    06/01/2021

    1.4

    Updated descriptions for Project Talent (Oxford/AstraZeneca) vaccine

    Addition of GTIN information to new packsizes

    Note – new dm+d additions not currently in SNOMED CT. Hyperlinks to be added once information available in SNOMED CT release.

    Jo Goulding

    20/01/2021

    1.5

    Addition of new dm+d concepts for ‘Renown’ vaccine (Moderna, Inc)

    New VTM for all vaccine products

    Note – new dm+d additions not currently in SNOMED CT. Hyperlinks to be added once information available in SNOMED CT release.

    Updated descriptions for ‘first dose’ SNOMED CT codes to reflect use in single dose vaccination schedules

    Jo Goulding

    01/02/2021

    1.6

    Amendments to Pfizer (‘Courageous’) vaccines:

    ·       Pack size change to 6 dose multidose vials (from 5 dose) Note – no change to product, only change to recommendations for use. Therefore, amended pack size descriptions not new products added.

    ·       Word order update in description to follow pattern from other vaccines

    ·       Supplier change to Pfizer Ltd

    Jo Goulding

    11/02/2021

    1.7

    Addition of new dm+d concepts for Valneva vaccine.

    Note – new dm+d additions not currently in SNOMED CT. Hyperlinks to be added once information available in SNOMED CT release.

    Jo Goulding

    19/03/2021

    1.8

    Addition of new dm+d concepts for Novavax vaccine

    Addition of single vial (10 dose) VMPP and AMPP concepts for Moderna vaccines

    Note – new dm+d additions not currently in SNOMED CT. Hyperlinks to be added once information available in SNOMED CT release.

    Jo Goulding


    SNOMED CT codes relating to COVID-19 Vaccination

    The following is the list of SNOMED CT procedure and product codes intended to support a mass vaccination campaigns in the UK specifically against COVID-19.

    The range and intended use of the codes shown here is similar to that already available for other established mass immunisation campaigns – in particular those for which the primary immunisation schedule also involves more than one vaccine dose administration event.

    However, unlike the SNOMED CT codesets available for some other national immunisation programmes, much of the administrative detail relating to a patient’s journey through a call:recall system are not covered. This aspect of running the overall campaign will be carried out by a central system that neither needs nor uses SNOMED CT codes specifically in order to represent (for example) when a patient has been sent an urgent SMS notification advising them of a late change to their next immunisation appointment date. Instead, many of the various patient states that this call-recall engine will be required to reason over will be represented only within that system and by some other non-SNOMED CT means, and does not need to be also shared more widely into other live clinical systems as SNOMED CT codes.

    The currently available SNOMED CT expressivity, therefore, aims to cover only the core clinical information about an individual’s immunisation journey that should be shareable with any other clinician for whom an understanding of the patient’s immunisation status could influence subsequent clinical decisions.

    Which specific vaccine preparation was used at any specific vaccination event will be co-recorded as a separate dm+d code for the vaccine preparation.

    The codeset is presented twice; first the raw list of codes and preferred terms and then again but with each code further accompanied by text clarifying its intended clinical meaning and scope.

    Scope

    This document only details SNOMED CT content related directly to COVID-19 Vaccination.

    It does not cover other SNOMED CT content pertaining to COVID-19 disease, complications, treatment etc. (e.g., 1325161000000102 Post-COVID-19 syndrome)


    CODE LIST FOR SARS-CoV-2 VACCINATION


    Codes shown in black are already published; those in red are new codes added in the 28 October 2020 release of SNOMED CT UK Edition and subsequent releases.
    (Codes are hyperlinked to termbrowser.nhs.uk)

    See following “list with scope notes” for further explanation.

    CLINICAL FINDING

    1240601000000108        High priority for SARS-CoV-2 vaccination 

    1240631000000102        Did not attend SARS-CoV-2 vaccination
    1324831000000104        Did not attend for first dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
    1324841000000108        Did not attend for second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine

    1324661000000105       Adverse reaction to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
    1324711000000102       Allergy to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine

    PROCEDURE

    1324671000000103 Immunisation course to achieve immunity against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)
    1324681000000101 Administration of first dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
    1324691000000104 Administration of second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine

    SITUATION WITH EXPLICIT CONTEXT

    1324731000000105 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course not indicated
    1324761000000100 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course contraindicated
    1324811000000107 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course declined
    1324821000000101 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course not done
    1324851000000106 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course started
    1324861000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course abandoned

    1324721000000108 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination dose declined
          1324741000000101 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination first dose declined
          1324751000000103 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination second dose declined
    1324771000000107 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination dose not given
          1324781000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination first dose not given
          1324791000000106 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination second dose not given

    PHARMACEUTICAL / BIOLOGIC PRODUCT

    All COVID-19 Vaccine VMPs linked to:

    VTM: 39330711000001103 COVID-19 vaccine

    Project Courageous (Pfizer):

    VMP: 39116111000001100 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials
    AMP: 39115611000001103 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd)

    VMPP: 39115311000001108 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials 6 dose

    VMPP: 39214411000001100 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials 1170 dose – 195 x 6 dose vials

    AMPP: 39115711000001107 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 6 dose

    AMPP: 39214511000001101 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 1170 dose – 195 x 6 dose vials                                        GTIN: 00359267100023

    Project Talent (AstraZeneca):

    VMP: 39116211000001106 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials
    AMP: 39114911000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 
    VMPP: 39114711000001108 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 8 dose
    VMPP: 39114811000001100 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 10 dose

    VMPP: 39301011000001100 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 80 dose 10 x 8 dose vials
    VMPP: 39301111000001104 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 100 dose 10 x 10 dose vials

    AMPP: 39115011000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 8 dose
    AMPP: 39115111000001106 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 10 dose

    AMPP: 39301211000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 80 dose 10 x 8 dose vials                                                        GTIN: 05000456063876
    AMPP: 39301311000001102 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 100 dose 10 x 10 dose vials                                      GTIN: 05000456063821

    Project Astute (Janssen-Cilag):

    VMP: 39233911000001100 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials
    AMP: 39230211000001104 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd) 
    VMPP: 39230011000001109 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials 5 dose
    VMPP: 39230111000001105 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials 50 dose
    AMPP: 39230311000001107 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials  (Janssen-Cilag Ltd) 5 dose
    AMPP: 39230411000001100 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd) 50 dose                                                                

    Project Renown (Moderna):

    VMP: 39326811000001106 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5mL dose dispersion for injection multidose vials
    AMP: 39326911000001101 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5mL dose dispersion for injection multidose vials (Moderna, Inc) 
    VMPP: 39375311000001106 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials 10 dose

    VMPP: 39326611000001107 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials 100 dose 10 x 10 dose vials

    AMPP: 39375411000001104 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 10 dose

    AMPP: 39327011000001102 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 100 dose 10 x 10 dose vials                                                                                      GTIN: 30380777700688

    Valneva:

    VMP: 39375211000001103 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials
    AMP: 39373511000001104 COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd)
    VMPP: 39373011000001107 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials 10 dose

    VMPP: 39373111000001108 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials 100 dose 10 x 10 dose vials
    AMPP: 39374411000001100 COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd) 10 dose

    AMPP: 39374711000001106 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd) 100 dose 10 x 10 dose vials                                       GTIN: 09120040710330

     
    Novavax:

    VMP: 39330711000001103 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials

    VMPP: 39472811000001101 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials 10 dose

    VMPP: 39472911000001106 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials 100 dose 10 x 10 dose vials

    AMP: 39473011000001103 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH)

    AMPP: 39473111000001102 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH) 10 dose

    AMPP: 39473211000001108 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH) 100 dose 10 x 10 dose vials                                                                        GTIN: 00380631100103

    END.               


    CODE LIST FOR SARS-CoV-2 VACCINATION, WITH SCOPE NOTES

    Codes shown in black are already published; those in red are proposed new codes.
    Codes in brown are published but now unlikely to be used.
    Codes in grey are published but now inactive and should never be used.

    CLINICAL FINDING

    1240601000000108  High priority for SARS-CoV-2 vaccination

                                      Subject is in one or more cohorts prioritised for vaccination 

    1240631000000102  Did not attend SARS-CoV-2 vaccination

    Subject did not attend a scheduled appointment where they were due to receive a vaccine dose.

    New entries into individual patient records should NEVER use this code: they should instead be expressed only using one of its child codes stating exactly which dose of the primary immunisation schedule had been missed.

    This code has value mainly only when constructing queries to retrieve patients who have missed either dose.

          1324831000000104 Did not attend for first dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine

    Subject did not attend a scheduled appointment where they were due to receive the first vaccine dose (or the only dose of a single dose schedule vaccine)              

          1324841000000108 Did not attend for second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine

                                            Subject did not attend a scheduled appointment where they were due to receive the second vaccine dose

    1324661000000105 Adverse reaction to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine
    1324711000000102 Allergy to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine

    Subject experienced some kind of adverse or allergic reaction to at least one vaccine dose.

    PROCEDURE

    1324671000000103 Immunisation course to achieve immunity against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)

    The idea of a course of therapy intended to induce an immunity to SARS-CoV-2 infection.
    This code exists mainly as a technical byproduct of creating the more specific codes (below) by which the stages of a course of treatment to immunise an individual patient can be recorded.
    When recorded on its own and “as is”, this code in fact indicates that such a course was completed on that record date; this code must therefore NOT be used to record when such a course has merely started.
    An immunisation course will comprise one or more vaccine dose administration events, to be coded as:

    1324681000000101 Administration of first dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine                              The subject was given the first dose of a vaccine against SARS-CoV-2 on the date recorded.

    This includes the administration of the only dose of a single dose schedule vaccine (need for a subsequent dose will be informed by inspecting the record of the specific vaccine used).

    1324691000000104 Administration of second dose of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccine                The subject was given the second dose of a vaccine against SARS-CoV-2 on the date recorded

    SITUATION WITH EXPLICIT CONTEXT

    1324731000000105 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course not indicated

    The subject has no clinical indication for commencing a primary immunisation schedule against SARS-CoV-2

    e.g. because they are not at (sufficient) risk.

    Different from saying that only one or other dose is not indicated, for which other codes exist.

    The course may be indicated at the start, but at some later point in time one of its doses is not.

    Conversely, however, if the course is not indicated at the outset then by implication none of its doses are either – though it is usually considered redundant to record both that the course as a whole is not indicated and also separately that neither dose is.

    1324761000000100 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course contraindicated

    The entire primary immunisation schedule was not started because of e.g. Immunosuppression or other comorbidity.

    Although usually permanent, such contraindications may be only temporary, and so the subject is not necessarily permanently excluded from all future enrolment in a course of vaccination.

    By contrast, contraindication to a dose (see below) is more likely to be only temporary .. but a more permanent contraindication to completing the schedule is also not excluded.
    Operationally, the presence of this code in the EPR as an active problem implies that no future vaccine doses should be given, at least not without careful clinical scrutiny of the record

    Note that other codes also carry this or a similar implication.

    See also the ‘vaccine dose contraindicated’ codes below.

    1324811000000107 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course declined

    The subject declined an offer to begin the primary immunisation schedule against SARS-CoV-2, and so was never invited to receive even the first dose
    Different from declining individual dosing events, for which separate codes exist.

    A subject may agree to being immunised, decline the first dose event due to temporary illness, be rescheduled and then go on to complete the course as planned

    1324851000000106 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course started

    The subject accepted an offer to begin the primary immunisation schedule against SARS-CoV-2, and either has been or will be invited to receive at least the first dose

    1324821000000101 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course not done

    The patient has a valid indication and did not decline vaccination, but the vaccination course was never started for some other reason (e.g. policy change)

    Different from “abandoned” (see below), which implies that the course WAS started

    1324861000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) immunisation course abandoned

    A primary immunisation course was started, but either zero or only the first dose was ever actually given before the attempt was permanently abandoned. No further doses will be given.

    Valid reasons for recording “abandoned” could include e.g. that the patient has unfortunately already contracted COVID-19 or developed a new contraindicaiton; the patient withdraws consent to proceed; the vaccine product has to be withdrawn from the market

    1. If a new contraindication emerges, this should always be recorded as at least a contraindication code.

    1240651000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination declined

    The subject declined to receive at least one vaccine dose

    Technically different from contraindicated but note that the reason a subject may decline an individual dose could include that they currently feel unwell, and the underlying suspected condition causing that illness may also be a contraindication.

    More common reasons could include e.g. that the appointment slot has become inconvenient or impractical for them to access, or that a child subject or needle phobic adult became too distressed to receive it

    New entries into individual patient records should however ideally not be made using this code but instead only using one of its child codes that specify which vaccine dose was declined.

    This code has value mainly only when constructing queries to retrieve patients for whom either dose was ever specifically declined

          1324741000000101 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination first dose declined

    The subject declined to receive the first vaccine dose (or the only dose of a single dose schedule vaccine), on the record date

    Where the vaccinator declines to administer the vaccine to the subject for any reason (e.g physical aggression from an elderly and confused subject), a different “not given” code should be used

          1324751000000103 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination second dose declined

    The subject declined to receive the second vaccine dose, on the record date

    Where the vaccinator declines to administer the vaccine to the subject for any reason (e.g physical aggression from an elderly and confused subject), a different “not given” code should be used

    1324771000000107 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination dose not given

                                      Administration of at least one vaccine dose could not be performed

    New entries into individual patient records should however ideally not be made using this code but instead only using one of its child codes that specify which vaccine dose was declined.

    This code has value mainly only when constructing queries to retrieve patients for whom either dose could not be given for any reason

          1324781000000109 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination first dose not given

    A scheduled administration of the first vaccine dose (or the only dose of a single dose schedule vaccine) could not be performed, on the record date, for any reason EXCEPT those separately codeable (did not attend, contraindicated, declined)

    Reasons could include e.g. lack of vaccine dose supply; aggressive behaviour toward the vaccinator by the subject

          1324791000000106 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination second dose not given

    A scheduled administration of the second vaccine dose could not be performed, on the record date, for any reason EXCEPT those separately codeable (did not attend, contraindicated, declined)

    Reasons could include e.g. lack of vaccine dose supply; aggressive behaviour toward the vaccinator by the subject

    PHARMACEUTICAL / BIOLOGIC PRODUCT

    39115611000001103 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd)

    39114911000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 

    39230211000001104 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd) 

    39326911000001101 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5mL dose dispersion for injection multidose vials (Moderna, Inc) 

    39373511000001104 COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd)

    39473011000001103 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH)

    The above codes correspond to the actual manufactured vaccine products (AMP) and should be used to share information concerning vaccine administration (i.e. to represent which vaccine was given to an individual patient). They must not be confused with other related codes (see below) corresponding to manufacturer packs containing more than one vaccine dose (VMPP and AMPP below) or to the abstract notion of a manufacturer-agnostic formulation (VMP).

    However, the GTIN (‘barcode’), when available, will be linked to the AMPP code and therefore AMPPs will need to be recognised for scanned input of product. Using relationships provided within dm+d natively and in its SNOMEDised derivative, AMPP codes obtained by scanning should then be coerced into a related AMP code (as above) in order for the AMP code only to be communicated as the record of the vaccine product actually administered to an individual patient.

    VMP: 39116111000001100 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials
    VMPP: 39115311000001108 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials 6 dose

    VMPP: 39214411000001100 Generic COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials 1170 dose – 195 x 6 dose vials

    AMPP: 39115711000001107 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 6 dose

    AMPP: 39214511000001101 COVID-19 mRNA Vaccine Pfizer-BioNTech BNT162b2 30micrograms/0.3ml dose concentrate for suspension for injection multidose vials (Pfizer Ltd) 1170 dose – 195 x 6 dose vials                               GTIN: 00359267100023

    VMP: 39116211000001106 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials
    VMPP: 39114711000001108 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 8 dose
    VMPP: 39114811000001100 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 10 dose

    VMPP: 39301011000001100 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 80 dose 10 x 8 dose vials
    VMPP: 39301111000001104 Generic COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials 100 dose 10 x 10 dose vials

    AMPP: 39115011000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 8 dose
    AMPP: 39115111000001106 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 10 dose

    AMPP: 39301211000001105 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 80 dose 10 x 8 dose vials                                                               GTIN: 05000456063876
    AMPP: 39301311000001102 COVID-19 Vaccine AstraZeneca (ChAdOx1 S [recombinant]) 5x10,000,000,000 viral particles/0.5ml dose solution for injection multidose vials (AstraZeneca) 100 dose 10 x 10 dose vials                                                                      GTIN: 05000456063821

    VMP: 39233911000001100 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials
    VMPP: 39230011000001109 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials 5 dose
    VMPP: 39230111000001105 Generic Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials 50 dose
    AMPP: 39230311000001107 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials  (Janssen-Cilag Ltd) 5 dose
    AMPP: 39230411000001100 Astute 100,000,000,000 (100 billion) viral particles/0.5ml dose solution for injection multidose vials (Janssen-Cilag Ltd) 50 dose

    VMP: 39326811000001106 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5mL dose dispersion for injection multidose vials
    VMPP: 39375311000001106 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials 10 dose

    VMPP: 39326611000001107 Generic COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials 100 dose 10 x 10 dose vials

    AMPP: 39375411000001104 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 10 dose

    AMPP: 39327011000001102 COVID-19 mRNA (nucleoside modified) Vaccine Moderna 0.1mg/0.5ml dose dispersion for injection multidose vials (Moderna, Inc) 100 dose 10 x 10 dose vials                                                                                                              GTIN: 30380777700688

    VMP: 39375211000001103 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials
    VMPP: 39373011000001107 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials 10 dose

    VMPP: 39373111000001108 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials 100 dose 10 x 10 dose vials
    AMPP: 39374411000001100 COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd) 10 dose

    AMPP: 39374711000001106 Generic COVID-19 Vaccine Valneva (inactivated adjuvanted whole virus) 40antigen units/0.5mL dose suspension for injection multidose vials (Valneva UK Ltd) 100 dose 10 x 10 dose vials                                                        GTIN: 09120040710330

    VMP: 39330711000001103 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials

    VMPP: 39472811000001101 Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials  10 dose

    VMPP: 39472911000001106  Generic COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials 100 dose 10 x 10 dose vials

    AMPP: 39473111000001102 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH) 10 dose

    AMPP: 39473211000001108 COVID-19 Vaccine Novavax (adjuvanted) 5micrograms/0.5ml dose suspension for injection multidose vials (Baxter Oncology GmbH) 100 dose 10 x 10 dose vials                                                                                                   GTIN: 00380631100103


    UNUSED

    The codes below, although both published and still active in SNOMED CT, are considered now unlikely to be used within the UK: 

    1240781000000106  SARS-CoV-2 vaccination invitation short message service text message sent 

    This code is expected to be supplanted within the national immunisation system by codes internal to that system.

    It is believed that this level of administrative detail does not need sharing into the wider clinical systems

    1240701000000101  SARS-CoV-2 vaccine not available

    This code is expected to be supplanted within the national immunisation system by codes internal to that system.

    It is believed that this level of administrative detail does not need sharing into the wider clinical systems.

    If a vaccine dose could not be administered because no dose was available, this may be messaged to the wider clinical system using one of the “dose not given” codes above.

    WITHDRAWN

    The codes below were added earlier in 2020 to the UK SNOMED Edition but are now made inactive and should not be used.

    1240491000000103 Severe acute respiratory syndrome coronavirus 2 vaccination (procedure)
    1240661000000107 Severe acute respiratory syndrome coronavirus 2 vaccination contraindicated (situation)
    1240651000000109 Severe acute respiratory syndrome coronavirus 2 vaccination declined (situation)
    1240681000000103 Severe acute respiratory syndrome coronavirus 2 vaccination not done (situation)
    1240671000000100 Severe acute respiratory syndrome coronavirus 2 vaccination not indicated (situation)

    END.

    Kind regards, 

    Terminology and Classifications Delivery Service

    Read All News Articles  

    By Claire Fennell 1 year ago

    Read this article

  • Delay to 31.0.0 SNOMED CT UK Edition Release

    Published: October 2020

    Dear colleague,

    Please note that due to a service disruption there has been a delay to the production of the 31.0.0 SNOMED CT UK Edition.

    This will delay the release of the:

    • SNOMED CT International Edition
    • SNOMED CT UK Clinical Extension
    • SNOMED CT UK Drug Extension

    The 31.0.0 SNOMED CT UK Edition will be published on Wednesday 11 November 2020, instead of its expected release date of Wednesday 04 November 2020.

    NHS Digital is sorry for any inconvenience that this will cause you.

    Kind regards

    Terminology & Classifications Delivery Service

    Read all news articles

    By Katy Park 2 years ago

    Read this article

  • Consultation on SNOMED CT Release Frequency and Changes to Subfolder Structure

    Published: September 2020

    Dear colleague,

    The uncertainty surrounding COVID-19 has necessitated the need for a rapid and responsive service beyond what our regular six-monthly release cycle can offer. We are running a consultation on our SNOMED CT UK Clinical Edition frequency for 2020 and beyond.

    Release Frequency

    We therefore propose a permanent shift to a minimum of seven scheduled releases of the UK Clinical Edition annually, made up of:

    • Two major releases annually in September/October and March, to update SNOMED CT UK Edition with the latest International Edition releases
    • Five minor releases of SNOMED CT UK Clinical Edition compromising of only incremental updates and other additions to UK Clinical Edition content
    • Unlike the 2020 “microreleases”, future minor releases will not be restricted to urgent COVID-19 related content only. Instead, all UK-specific “business as usual” content that was previously released only in two batches (April and October) will become distributed more or less equally across the full set of seven or more annual releases, both major and minor.
    • The SNOMED CT Drug Edition four-weekly release cycle will remain unchanged: each release of SNOMED CT UK Clinical Edition will always co-occur with a scheduled release of the Drug Edition.

    Should the clinical need arise, this typical annual schedule of seven releases may exceptionally be supplemented by one or more additional unscheduled emergency releases; these would however also occur on the same date as the next scheduled release of the UK Drug Edition. The proposed continuing release schedule is therefore fundamentally based on the underlying 4-weekly cycle time of the UK Drug Edition:

    Planned changes to the SNOMED CT UK Edition release subfolder structure

    From the first scheduled release in 2021 (27 January 2021), all PRODUCTION releases of UK Clinical and Drug will adopt the BETA encoding structure. All releases of both UK Clinical and UK Drug Editions will continue to be published in parallel in both the older LEGACY encoding as well as in the new PRODUCTION encoding, but only until the end of March 2021 after which the LEGACY encoding will be permanently withdrawn

    For a more detailed explanation of the motivations for the BETA bundling, see the webinar recording at this location.  Detailed information is also provided in the UK Clinical Edition SNOMED CT Technical overview document, section 2.4.1 and 2.4.2. 

    Throughout the remainder of 2020, PRODUCTION releases will remain as before but with the same content always co-published on TRUD in BETA format, as Test Releases: Clinical Edition and Drug Extension 29.3.0, RF2, BETA: Full, Snapshot & Delta.

    Kind regards

    Terminology and Classifications Delivery Service 

    Read all news articles

    By Katy Park 2 years ago

    Read this article

  • Revised Autumn 2020 Schedule for UK SNOMED Releases

    Published: August 2020

    Dear Colleague,

    The next scheduled combined releases of the SNOMED UK Clinical and Drug Extensions, on 07 October, were both planned to be “major releases” involving very substantial changes imposed by rebasing the content on the latest July 2020 SNOMED CT International Edition.

    Unfortunately, technical teething issues with an upgrade to our NHS Digital SNOMED CT authoring platform have eaten too far into our authoring contingency time. We have, therefore, reluctantly taken the decision to descope that “content rebasing” element from both 07 October 2020 releases.

    Whilst there will still be 07 October 2020 releases for both extensions, they are both now descoped to being only a 30.2.0 “minor release”: both will remain based on the July 2019 SNOMED CT International Edition (as for the existing 30.0.0 releases). The SNOMED CT UK Clinical Extension will add only fairly modest quantities of new UK content, some of which will be specific to managing COVID-19 but most of which will not. The 30.2.0 SNOMED CT UK Drug Extension release will be a normal four-weekly release , following the immediately preceding release of 30.1.0 SNOMED CT UK Drug Extension scheduled for 9 September 2020.

    The originally planned “major release” element will, therefore, now occur at a new, previously unscheduled combined release on 04 November 2020, in which all content to date in both extensions will finally become simultaneously rebased to the July 2020 SNOMED CT International Edition. Deferring until the already scheduled 02 December 2020 release date was considered, but many suppliers had previously expressed a strong preference against “major releases” in December 2020.

    The  revised release schedule to the end of 2020 is, therefore:

    07 October 2020

    TRUD Version 30.2.0
    EffectiveTime 20200930
    Base Content July 2019 SNOMED CT International Edition (the same as 30.0.0 12 August 2020)
    New Content
    • Additional routine non-COVID-19 content for the UK
    • Any requested new COVID-19 content (as per a microrelease)
    • Full ICD-10 and OPCS-4 maps covering above new content
    • Full updates of refsets to align with new content

     

     

     

     

     

     

     


    04 November 2020

    TRUD Version 31.0.0
    EffectiveTime 20201028
    Base Content July 2020 SNOMED CT International Edition
    New Content
    • Additional routine non-COVID-19 content for the UK
    • Any requested new COVID-19 content (as per a microrelease)
    • Full ICD-10 and OPCS-4 maps covering above new content
    • Full updates of refsets to align with new content



     

     

     

     



    02 December 2020

    TRUD Version 31.1.0
    EffectiveTime 20201125
    Base Content July 2020 SNOMED CT International Edition
    New Content
    • Additional routine non-COVID-19 content for the UK
    • Any requested new COVID-19 content (as per a microrelease)
    • Full ICD-10 and OPCS-4 maps covering above new content
    • Full updates of refsets to align with new content


    Kind regards,

    Terminology & Classifications Delivery Service

    Read all news articles

    By Katy Park 2 years ago

    Read this article

  • Known issues with the Module Dependency Refset (MDR) file

    Published: August 2020

    Dear Colleague,

    The 15 April 2020 MDR release included some off-specification duplicate rows in which the same ID and effectiveTime appeared twice, but with different data. Attempts to build the standard unique composite key on {ID, effectiveTime} on the FULL data as distributed will therefore fail.

    The IDs and effectiveTimes involved are:

    • f0658b79-0cbc-116a-e044-0003ba13161a             20200415
    • f0658b79-0cbd-116a-e044-0003ba13161a            20200415

    This technical error has subsequently been published in all FULL file distributions made since 15 April.

    The error can not be removed by means of a further Delta, but is scheduled to be expunged from the distributed FULL files from the 7 October 2020 release.

    For those affected by the error, a range of mitigations exist:

    1. Do not load (or index) the MDR content at all, if it is not in fact required by your application.
    2. Depart from the specification and apply a non-unique index over {ID, effectiveTime}. Extraction of the latest snapshot of the MDR would not be adversely affected.
    3. Manually delete the erroneous data from the FULL table, before then proceeding with the usual unique indexation:

    DELETE FROM snomed.rf2_ssrefset_full
    WHERE ID IN (‘f0658b79-0cbc-116a-e044-0003ba13161a’,’f0658b79-0cbd-116a-e044-0003ba13161a’)
    AND effectiveTime = ‘20200415’
    AND linkedString1 = ‘20200401’;

        4. (From 7 October release) Replace your current cumulative FULL data for this table with a copy of a newer distribution, from which the error has  already been removed at source.

    Finally, NHS Digital would welcome more direct engagement with those who encounter this error, and especially those whose applications actively use the MDR data. We are keen to understand user expectations and experiences with it to date, and discuss other known MDR historical issues and plans for its future development.

    Kind regards,

    Terminology & Classifications Delivery Service

    Read all news articles

    By Katy Park 2 years ago

    Read this article

  • April 2020 SNOMED CT Biannual Release (includes COVID-19 content)

    Published: April 2020

    Dear colleague,

    The SNOMED CT UK Clinical Edition, RF2 for April 2020 is now available for download from the following links:

    The SNOMED CT UK Drug extension is not released as part of the SNOMED CT biannual release. SNOMED CT UK Drug Extension data is published on a four-weekly cycle within the "UK Drug Extension, RF2" sub pack on TRUD. Please review the associated documentation for more details.

    Release documentation is now only accessible on Delen.

    Important changes and information regarding this release

    Although a release was always scheduled for April 2020, its content changes have been radically descoped and are now restricted to coding expressivity improvements urgently needed to manage the current pandemic. This very narrowed scope should reduce the “content update penalty” on product consumers, and so reduce barriers to the urgent deployment of the new content to the clinical frontline:

    Whereas this release had been planned to be based on the July 2019 International Edition, it remains instead based on the July 2018 International Edition.

    A new tranche of 30 COVID-19 codes are added relating to the current pandemic, in addition to those already released for that same purpose in the 28.1.1 Emergency Release of February 2020. The 30 new codes are:

    1300671000000104

    COVID-19 severity scale

    (assessment scale)

    1321071000000107

    Has NHS digital isolation note

    (finding)

    1321081000000109

    Self-isolation note issued to patient

    (finding)

    1321091000000106

    Household isolation note issued to patient

    (finding)

    1300591000000101

    Low risk category for developing complication from COVID-19 infection

    (finding)

    1300571000000100

    Moderate risk category for developing complication from COVID-19 infection

    (finding)

    1300561000000107

    High risk category for developing complication from COVID-19 infection

    (finding)

    1300631000000101

    COVID-19 severity score

    (observable entity)

    1300681000000102

    Assessment using COVID-19 severity scale

    (procedure)

    1321161000000104

    Household isolation to prevent exposure of community to contagion

    (procedure)

    1321131000000109

    Self-isolation to prevent exposure of community to contagion

    (procedure)

    1321141000000100

    Shielding of household to prevent exposure of uninfected subject to contagion

    (procedure)

    1321151000000102

    Shielding of uninfected subject to prevent exposure to contagion

    (procedure)

    1321231000000101

    Signposting to CHMS (COVID-19 Home Management Service)

    (procedure)

    1321061000000100

    Signposting to NHS online isolation note service

    (procedure)

    1320971000000102

    Taking of swab for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)

    (procedure)

    1300721000000109

    COVID-19 confirmed by laboratory test

    (situation)

    1300731000000106

    COVID-19 confirmed using clinical diagnostic criteria

    (situation)

    1321101000000103

    COVID-19 excluded

    (situation)

    1321111000000101

    COVID-19 excluded by laboratory test

    (situation)

    1321121000000107

    COVID-19 excluded using clinical diagnostic criteria

    (situation)

    1321221000000103

    Consultation via video conference not available

    (situation)

    1321171000000106

    Provision of advice, assessment or treatment limited due to COVID-19 pandemic

    (situation)

    1321031000000105

    Self-taken swab for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) completed

    (situation)

    1321041000000101

    Self-taken swab for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) offered

    (situation)

    1321051000000103

    Swab for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) taken by healthcare professional

    (situation)

    1321201000000107

    COVID-19 health issues simple reference set

    (foundation metadata concept)

    1321211000000109

    COVID-19 presenting complaints simple reference set

    (foundation metadata concept)

    1321191000000105

    COVID-19 procedures simple reference set

    (foundation metadata concept)

    1321181000000108

    COVID-19 record extraction simple reference set

    (foundation metadata concept)


    N.B. The final four items in this list are four new refsets holding elements of both this new content and of the COVID-19 content added back in February in the 28.1.1 release.

    Only nine new non-COVID-19 items were added, largely for technical reasons (they have already been pre-released):

    1126441000000105

    Office of Population Censuses and Surveys Classification of Interventions and Procedures Version 4.9 complex map reference set

    (foundation metadata concept)

    1149501000000101

    List of consultations

    (record artifact)

    1218611000000102

    Urgent supply of prescription items by community pharmacy

    (record artifact)

    1239801000000104

    Survivor of conflagration in residential building or apartment

    (finding)

    1239831000000105

    Bereavement due to conflagration in residential building or apartment

    (finding)

    1239791000000103

    Major incident bereavement support management

    (procedure)

    1239781000000100

    Major incident survivor annual review

    (regime/therapy)

    1239771000000102

    Major incident survivor monitoring

    (regime/therapy)

    1239861000000100

    Seasonal influenza vaccination given in school

    (situation)


    Further incremental “microreleases” of the UK SNOMED CT Clinical Extension will occur with new COVID-19 related content for the NHS. These will coincide with at least the next three scheduled releases of the UK SNOMED CT Drug Extension (22 April, 20 May and 17 June). A full release comprised of substantially all new content deferred from this current scheduled 1 April release is planned for October 2020. However, the ongoing effects and requirements of the pandemic may require this plan to change; the final contents of the October 2020 release will be informed by a consultation that NHS Digital will carry out in July to assess readiness of the NHS and its IT suppliers.

    Subscribers were previously advised that, from April 2020 all future PRODUCTION releases of the Drug and Clinical extension content would transition to the BETA release bundling previously provided as technology previews here. This transition is also now deferred: the PRODUCTIION release will remain as before; BETA format releases will continue to be published alongside.

    For a more detailed explanation of the issues behind the BETA bundling, watch our webinar recording.

    Reference sets (Refsets)

    There are 4 new UK refsets for the April 2020 release, as detailed above. All are relevant to COVID-19.

    Cross Mapping

    The SNOMED CT to OPCS-4.8, OPCS-4.9 and ICD-10 5th Edition five character maps are included in this April 2020 bi-annual release. The ICD-10 four character only maps reference set (999002261000000108) has been removed completely from the release from June 2019 onwards.

    Kind regards

    Terminology & Classifications Delivery Service

    Read all news articles

    By Katy Park 2 years ago

    Read this article

  • UK SNOMED CT Clinical Edition – April 2020 release – COVID-19 content

    Published: March 2020

    Dear colleague,

    The planned biannual release of the UK SNOMED CT Clinical Edition on the 1st April will be replaced with a significantly smaller version in order to add COVID-19 content and a small amount of high priority concepts.

    The content originally planned to be released on the 1 April 2020 was expected to include additions to the following domains digital child health, new-born blood spot screening, IAPT and mental health as well as new international content.   However, in light of the current pandemic, we recognise that such large-scale changes to the coding framework could impose a significant assurance and change management burden on system suppliers, which may delay the deployment of any care-critical COVID-19 elements. Because of this the full release with these additions has been cancelled. 

    Further similarly small COVID-19 releases may follow in the weeks ahead as new coding requirements emerge.  Any other interim requirements will be considered in consultation with the wider NHS and relevant stakeholders.

    The next full release will follow our schedule for October 2020.

    Kind regards

    Terminology & Classifications Delivery Service

    Read all news articles

    By Katy Park 2 years ago

    Read this article

Older articles